# US 2025/0146073 A1 · Methods for the treatment of scn2a-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146073 A1
- Document ID: US20250146073A1
- Status: Published application
- Kind: A1
- Application number: 18/834,440
- Filed: 2023-02-03
- Published: 2025-05-08
- Earliest claimed: 2022-02-04
- Assignees: Praxis Precision Medicines, Inc.
- Applicants: Praxis Precision Medicines, Inc.
- Inventors: Kelley Dalby
- Web page: https://patentgrep.com/patent/US20250146073A1

## CPC

- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61P 25/08: Antiepileptics; Anticonvulsants
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure features useful methods to treat a SCN2A-related disorder caused by a gain-of-function SCN2A mutation using an SCN2A inhibitor. The present disclosure also features useful methods to treat a SCN2A-related disorder caused by a loss-of-function SCN2A mutation using an SCN2A enhancer. By monitoring the early onset seizure status of a subject, appropriate treatments can be administered more quickly without having to verify whether the subject has a gain-of-function or loss-of-function SCN2A mutation.

## Claims

### Claim 1

A method for treating a subject with a SCN2A-related disorder caused by a gain-of-function SCN2A mutation, the method comprising:
determining whether the subject has had an early onset seizure; and
administering a SCN2A inhibitor to the subject if the subject has had an early onset seizure,
wherein the method does not comprise experimentally verifying that the subject's SCN2A mutation as a gain-of-function mutation or confirming that the subject's SCN2A mutation has previously been experimentally verified as a gain-of-function mutation prior to administering the SCN2A inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the early onset seizure occurred within the first three months, the first two and a half months, the first two months, the first month and a half, the first month, the first four weeks, the first three weeks, the first two weeks, the first week, the first day of the subject's life, or while the subject was in utero.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, further comprising determining that the subject carries a SCN2A mutation prior to administering the SCN2A inhibitor without experimentally verifying that the SCN2A mutation is a gain-of-function mutation or confirming that the SCN2A mutation has previously been experimentally verified as a gain-of-function mutation prior to administering the SCN2A inhibitor.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the SCN2A mutation is A263V, E430A, R1882Q, G879R, G1593R, K1502N, V1601L, G211D, S1780I, D343H, or combinations of the foregoing.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the subject is less than 18 years old.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the SCN2A-related disorder caused by a gain-of-function SCN2A mutation is Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, or early onset epileptic encephalopathy.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the SCN2A inhibitor is administered intrathecally, intramedullarly, intracerebroventricularly, or parenterally.

### Claim 8 (depends on 7)

The method of claim 7, wherein the parenteral administration is subcutaneous, intravenous, or intramuscular injection or infusion.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the SCN2A inhibitor is a CRISPR-Cas repressor, a SCN2A channel blocker, an antibody, or a nucleic acid inhibitor molecule, such as an antisense oligonucleotide or an siRNA.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antisense oligonucleotide comprises a single-stranded oligonucleotide that is 10-80 nucleosides in length and comprises a nucleobase sequence comprising a portion of 10 contiguous nucleobases having at least 80% complementary to an equal length portion of a target region of a pre-mRNA transcript or an mRNA transcript of a human SCN2A gene, in an amount and for a duration sufficient to treat the SCN2A-related disorder caused by a gain-of-function SCN2A mutation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method decreases expression of the human SCN2A gene.

### Claim 12 (depends on 10, 11)

The method of claim 10 or claim 11, wherein the oligonucleotide comprises, consists essentially of, or consists of a nucleobase sequence complementary to a portion of SCN2A mRNA that encodes the amino acid sequence of SEQ ID NO: 1.

### Claim 13 (depends on 10, 11, 12)

The method of any one of claims 10-12, wherein the oligonucleotide comprises one or more modified sugars, one or more modified internucleoside linkages, and/or one or more modified nucleobases.

### Claim 14 (depends on 13)

The method of claim 13, wherein the oligonucleotide comprises one or more modified sugars.

### Claim 15 (depends on 14)

The method of claim 14, wherein each of the one or more modified sugars is independently selected from the group consisting of a bicyclic sugar, a 2′-O-methoxyethyl (2MOE) modified sugar, a 2′-O-methyl (2-OMe) modified sugar, a 2′-methoxy modified sugar, a 2′-Fluoro modified sugar, a 2′-O-alkyl modified sugar, a constrained ethyl (cEt) modified sugar, a locked sugar, and an unlocked sugar.

### Claim 16 (depends on 15)

The method of claim 15, wherein each nucleoside of the oligonucleotide comprises a 2MOE modified sugar.

### Claim 17 (depends on 13, 14, 15, 16)

The method of any one of claims 13-16, wherein the oligonucleotide comprises one or more modified internucleoside linkages.

### Claim 18 (depends on 17)

The method of claim 17, wherein one or more of the modified internucleoside linkages comprises a modified phosphate.

### Claim 19 (depends on 18)

The method of claim 18, wherein each of the modified phosphates is independently selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidate, a phosphorodiamidate, a thiophosphoramidate, a thiophosphorodiamidate, a methyl phosphonate, a phosphoromorpholidate, and a phosphoropiperazidate.

### Claim 20 (depends on 19)

The method of claim 19, wherein each internucleoside linkage of the oligonucleotide is a phosphorothioate internucleoside linkage.

### Claim 21 (depends on 20)

The method of claim 20, wherein the each phosphorothioate internucleoside linkage is a phosphorodiamidate morpholino internucleoside linkage.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 13-21, wherein the oligonucleotide comprises one or more modified nucleobases.

### Claim 23 (depends on 22)

The method of claim 22, wherein the modified nucleobase is selected from the group consisting of 5-methylcytosine, 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propyladenine, 2-propylguanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-halocytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 8-haloadenine, 8-aminoadenine, 8-thioladenine, 8-thioalkyladenine, 8-hydroxyladenine, 8-haloguanine, 8-aminoguanine, 8-thiolguanine, 8-thioalkylguanine, 8-hydroxylguanine, 5-bromouracil, 5-trifluoromethyluracil, 5-bromocytosine, 5-trifluoromethylcytosine, 7-methylguanine, 7-methyladenine, 2-fluoroadenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

### Claim 24 (depends on 23)

The method of claim 23, wherein the modified nucleobase is a 5-methylcytosine.

### Claim 25 (depends on 24)

The method of claim 24, wherein each cytosine in the oligonucleotide is a 5-methylcytosine.

### Claim 26 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 13-25, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides; wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

### Claim 27 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 10-26, wherein the oligonucleotide consists of 12 to 40 nucleobases.

### Claim 28 (depends on 27)

The method of claim 27, wherein the oligonucleotide consists of 16 to 30 nucleobases.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the method comprises inhibiting the expression of SCN2A in neuronal cells in the subject.

### Claim 30 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 10-29, wherein the oligonucleotide is selective for SCN2A pre-mRNA or mRNA over SCN1A pre-mRNA or mRNA.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A composition comprising an SCN2A inhibitor for use in the methods of any one of claims 1-30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

Use of an SCN2A inhibitor for treating a subject with a SCN2A-related disorder caused by a gain-of-function SCN2A mutation according to the method of any one of claims 1-30.

### Claim 33

A method for treating a subject with a SCN2A-related disorder caused by a loss-of-function SCN2A mutation, the method comprising:
determining whether the subject has had an early onset seizure; and
administering a SCN2A enhancer to the subject if the subject has not had an early onset seizure,
wherein the SCN2A enhancer is administered as a second line therapy or is co-administered with a first line therapy if the subject has infantile spasms, and wherein the method does not comprise experimentally verifying the subject's SCN2A mutation as a loss-of-function mutation or confirming that the subject's SCN2A mutation has previously been experimentally verified as a loss-of-function mutation prior to administering the SCN2A enhancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the first line therapy is steroids, adrenocorticotropic hormone (ACTH), or vigabatrin.

### Claim 35 (depends on 33, 34)

The method of claim 33 or claim 34, wherein the subject had no seizure within the first six months, within the first five months, within the first four months, within the first three months, within the first two and a half months, within the first two months, within the first month, or within the first four weeks of the subject's life.

### Claim 36 (depends on 33, 34, 35)

The method of any one of claims 33-35, further comprising determining that the subject carries a SCN2A mutation prior to administering the SCN2A enhancer without experimentally verifying that the SCN2A mutation is a loss-of-function mutation or confirming that the SCN2A mutation has previously been experimentally verified as a loss-of-function mutation prior to administering the SCN2A enhancer.

### Claim 37 (depends on 33, 34, 35, 36)

The method of any one of claims 33-36, wherein the SCN2A mutation comprises M951R, F1375V, R853Q, A1773T, R571H, K1422E, D195G, Y428, K507E, Y1771H, S1758R, or combinations of the foregoing.

### Claim 38 (depends on 33, 34, 35, 36, 37)

The method of any one of claims 33-37, wherein the subject is less than 18 years old.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The method of any one of claims 33-38, wherein the SCN2A-related disorder caused by a loss-of-function SCN2A mutation is autism spectrum disorder, benign familial neonatal/infantile seizures, infantile spasms, Ohtahara syndrome, late seizure onset epileptic encephalopathy, or epilepsy of infancy with migrating focal seizures.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 33-39, wherein the SCN2A enhancer is administered intrathecally, intramedullarly, intracerebroventricularly, or parenterally.

### Claim 41 (depends on 40)

The method of claim 40, wherein the parenteral administration is subcutaneous, intravenous, or intramuscular injection or infusion.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 33-41, wherein the SCN2A enhancer is an antisense oligonucleotide, a CRISPR-Cas enhancer, an antibody, or a SCN2A activator.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antisense oligonucleotide comprises a single-stranded oligonucleotide that is 10-80 nucleosides in length and comprises a nucleobase sequence comprising a portion of 10 contiguous nucleobases having at least 80% complementary to an equal length portion of a target region of a pre-mRNA transcript or an mRNA transcript of a human SCN2A gene, in an amount and for a duration sufficient to treat the SCN2A-related disorder caused by a loss-of-function SCN2A mutation.

### Claim 44 (depends on 43)

The method of claim 43, wherein the method increases expression of the human SCN2A gene.

### Claim 45 (depends on 43, 44)

The method of claim 43 or claim 44, wherein the oligonucleotide comprises, consists essentially of, or consists of a nucleobase sequence complementary to a portion of SCN2A mRNA that encodes the amino acid sequence of SEQ ID NO: 1.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43-45, wherein the oligonucleotide comprises one or more modified sugars, one or more modified internucleoside linkages, and/or one or more modified nucleobases.

### Claim 47 (depends on 46)

The method of claim 46, wherein the oligonucleotide comprises one or more modified sugars.

### Claim 48 (depends on 47)

The method of claim 47, wherein each of the one or more modified sugars is independently selected from the group consisting of a bicyclic sugar, a 2′-O-methoxyethyl (2MOE) modified sugar, a 2′-O-methyl (2-OMe) modified sugar, a 2′-methoxy modified sugar, a 2′-Fluoro modified sugar, a 2′-O-alkyl modified sugar, a constrained ethyl (cEt) modified sugar, a locked sugar, and an unlocked sugar.

### Claim 49 (depends on 48)

The method of claim 48, wherein each nucleoside of the oligonucleotide comprises a 2MOE modified sugar.

### Claim 50 (depends on 46, 47, 48, 49)

The method of any one of claims 46-49, wherein the oligonucleotide comprises one or more modified internucleoside linkages.

### Claim 51 (depends on 50)

The method of claim 50, wherein one or more of the modified internucleoside linkages comprises a modified phosphate.

### Claim 52 (depends on 51)

The method of claim 51, wherein each of the modified phosphates is independently selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidate, a phosphorodiamidate, a thiophosphoramidate, a thiophosphorodiamidate, a methyl phosphonate, a phosphoromorpholidate, and a phosphoropiperazidate.

### Claim 53 (depends on 52)

The method of claim 52, wherein each of the internucleoside linkages of the oligonucleotide is a phosphorothioate internucleoside linkage.

### Claim 54 (depends on 53)

The method of claim 53, wherein each of the phosphorothioate internucleoside linkages is a phosphorodiamidate morpholino internucleoside linkage.

### Claim 55 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 43-54, wherein the oligonucleotide comprises one or more modified nucleobases.

### Claim 56 (depends on 55)

The method of claim 55, wherein the modified nucleobase is selected from the group consisting of 5-methylcytosine, 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propyladenine, 2-propylguanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, 5-halocytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-uracil (pseudouracil), 4-thiouracil, 8-haloadenine, 8-aminoadenine, 8-thioladenine, 8-thioalkyladenine, 8-hydroxyladenine, 8-haloguanine, 8-aminoguanine, 8-thiolguanine, 8-thioalkylguanine, 8-hydroxylguanine, 5-bromouracil, 5-trifluoromethyluracil, 5-bromocytosine, 5-trifluoromethylcytosine, 7-methylguanine, 7-methyladenine, 2-fluoroadenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

### Claim 57 (depends on 56)

The method of claim 56, wherein the modified nucleobase is a 5-methylcytosine.

### Claim 58 (depends on 57)

The method of claim 57, wherein each cytosine of the oligonucleotide is a 5-methylcytosine.

### Claim 59 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 43-58, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides; wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

### Claim 60 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 43-59, wherein the oligonucleotide consists of 12 to 40 nucleobases.

### Claim 61 (depends on 60)

The method of claim 60, wherein the oligonucleotide consists of 16 to 30 nucleobases.

### Claim 62 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 33-61, wherein the method comprises increasing the expression of SCN2A in neuronal cells in the subject.

### Claim 63 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 43-62, wherein the oligonucleotide is selective for SCN2A pre-mRNA or mRNA over SCN1A pre-mRNA or mRNA.

### Claim 64 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A composition comprising an SCN2A enhancer for use in the methods of any one of claims 33-63.

### Claim 65 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

Use of an SCN2A enhancer for treating a subject with a SCN2A-related disorder caused by a loss-of-function SCN2A mutation according to the method of any one of claims 33-63.
